HK1204982A1 - Stabilized pharmaceutical formulations of a potent hcv inhibitor - Google Patents

Stabilized pharmaceutical formulations of a potent hcv inhibitor Download PDF

Info

Publication number
HK1204982A1
HK1204982A1 HK15105856.5A HK15105856A HK1204982A1 HK 1204982 A1 HK1204982 A1 HK 1204982A1 HK 15105856 A HK15105856 A HK 15105856A HK 1204982 A1 HK1204982 A1 HK 1204982A1
Authority
HK
Hong Kong
Prior art keywords
composition
compound
liquid pharmaceutical
pharmaceutical composition
less
Prior art date
Application number
HK15105856.5A
Other languages
English (en)
Chinese (zh)
Inventor
Mathias Braun
Carl Alan Busacca
Feng-Jing Chen
Edwin Louis GUMP
Jenness B. MAJESKA
Scott PENNINO
Fenghe QIU
Maria Fernanda Villagra
Original Assignee
勃林格殷格翰国际有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1204982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 勃林格殷格翰国际有限公司 filed Critical 勃林格殷格翰国际有限公司
Publication of HK1204982A1 publication Critical patent/HK1204982A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15105856.5A 2012-01-12 2013-01-10 Stabilized pharmaceutical formulations of a potent hcv inhibitor HK1204982A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12
US61/586,087 2012-01-12
PCT/US2013/020934 WO2013106506A1 (en) 2012-01-12 2013-01-10 Stabilized pharmaceutical formulations of a potent hcv inhibitor

Publications (1)

Publication Number Publication Date
HK1204982A1 true HK1204982A1 (en) 2015-12-11

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105856.5A HK1204982A1 (en) 2012-01-12 2013-01-10 Stabilized pharmaceutical formulations of a potent hcv inhibitor

Country Status (27)

Country Link
US (2) US20140037719A1 (pm)
EP (1) EP2802313A1 (pm)
JP (1) JP2015503616A (pm)
KR (1) KR20140109433A (pm)
CN (1) CN104244926A (pm)
AP (1) AP2014007760A0 (pm)
AR (1) AR089710A1 (pm)
AU (1) AU2013208024A1 (pm)
BR (1) BR112014017058A8 (pm)
CA (1) CA2861041A1 (pm)
CL (1) CL2014001783A1 (pm)
CO (1) CO7000774A2 (pm)
EA (1) EA201400808A1 (pm)
EC (1) ECSP14013104A (pm)
HK (1) HK1204982A1 (pm)
IL (1) IL233550A0 (pm)
IN (1) IN2014DN05759A (pm)
MA (1) MA35865B1 (pm)
MX (1) MX2014008205A (pm)
NZ (1) NZ626353A (pm)
PE (1) PE20141817A1 (pm)
PH (1) PH12014501598A1 (pm)
SG (1) SG11201404042VA (pm)
TN (1) TN2014000295A1 (pm)
TW (1) TW201340969A (pm)
UY (1) UY34569A (pm)
WO (1) WO2013106506A1 (pm)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
CN1791599A (zh) 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
US7514557B2 (en) 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
EP2331538B1 (en) 2008-09-16 2014-04-16 Boehringer Ingelheim International GmbH Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
RS53121B (en) * 2008-11-21 2014-06-30 Boehringer Ingelheim International Gmbh PHARMACEUTICAL COMPOSITION OF POWERFUL HCV INHIBITOR FOR ORAL USE
BR112012000287B8 (pt) * 2009-07-07 2021-05-25 Boehringer Ingelheim Int composição farmacêutica para um inibidor de protease viral de hepatite c

Also Published As

Publication number Publication date
CL2014001783A1 (es) 2014-12-12
MX2014008205A (es) 2014-08-08
IL233550A0 (en) 2014-08-31
SG11201404042VA (en) 2014-08-28
TW201340969A (zh) 2013-10-16
KR20140109433A (ko) 2014-09-15
PE20141817A1 (es) 2014-12-17
MA35865B1 (fr) 2014-12-01
AP2014007760A0 (en) 2014-07-31
WO2013106506A1 (en) 2013-07-18
US20140037719A1 (en) 2014-02-06
BR112014017058A8 (pt) 2017-07-04
CN104244926A (zh) 2014-12-24
US20150190458A1 (en) 2015-07-09
UY34569A (es) 2013-07-31
ECSP14013104A (es) 2015-11-30
AU2013208024A1 (en) 2014-07-10
CO7000774A2 (es) 2014-07-21
TN2014000295A1 (en) 2015-12-21
PH12014501598A1 (en) 2014-10-08
CA2861041A1 (en) 2013-07-18
IN2014DN05759A (pm) 2015-04-10
EP2802313A1 (en) 2014-11-19
NZ626353A (en) 2016-02-26
BR112014017058A2 (pt) 2017-06-13
EA201400808A1 (ru) 2015-02-27
AR089710A1 (es) 2014-09-10
JP2015503616A (ja) 2015-02-02

Similar Documents

Publication Publication Date Title
CN102470103B (zh) 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
US20220096434A1 (en) Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
WO2013169406A1 (en) Manufacturing and packaging room temperature stable dronabinol capsules
AU2017331591B2 (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
HK1204982A1 (en) Stabilized pharmaceutical formulations of a potent hcv inhibitor
EP1344523A1 (en) Ibuprofen solution for hard gelatin capsules
US7029698B2 (en) Acetaminophen compositions
OA16937A (en) Stabilized pharmaceutical formulations of a potent HCV inhibitor.
CA3011685C (en) Stable trientine formulations
KR20020039354A (ko) 바소프레신 길항제 제형 및 방법
HK1233162A1 (en) Formulations of cyclophosphamide liquid concentrate
HK1187495A1 (en) Clevidipine emulsion formulations containing antimicrobial agents
HK1187495B (en) Clevidipine emulsion formulations containing antimicrobial agents